$CVS
CVS HEALTH Corp Stock $cvs

$cvs Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000006480321000017 Filed on May 04, 2021

Income Statement

Concept	2021 Q1	2020 Q4	2020 Q1
Revenue	$69.10B	$69.55B	$66.76B
YoY Change	3.51%	3.98%	8.29%
Cost Of Revenue	$40.89B	$42.45B	$40.35B
YoY Change	1.36%	0.92%	8.32%
Gross Profit	$28.20B	$27.10B	$26.41B
YoY Change	6.8%	9.18%	8.23%
Gross Profit Margin	40.82%	38.97%	39.56%
Selling, General & Admin	$8.881B	$9.295B	$8.494B
YoY Change	4.56%	10.73%	4.32%
% of Gross Profit	31.49%	34.3%	32.16%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.126B		$1.086B
YoY Change	3.68%		-2.25%
% of Gross Profit	3.99%		4.11%
Operating Expenses	$8.922B	$24.44B	$8.563B
YoY Change	4.19%	13.53%	3.79%
Operating Profit	$3.577B	$2.662B	$3.458B
YoY Change	3.44%	-12.35%	28.55%
Interest Expense	$657.0M	-$678.0M	$733.0M
YoY Change	-10.37%	-7.63%	-6.27%
% of Operating Profit	18.37%	-25.47%	21.2%
Other Income/Expense, Net	$50.00M	$53.00M	$54.00M
YoY Change	-7.41%	70.97%	74.19%
Pretax Income	$2.970B	$1.225B	$2.779B
YoY Change	6.87%	-47.51%	43.32%
Income Tax	$746.0M	$241.0M	$767.0M
% Of Pretax Income	25.12%	19.67%	27.6%
Net Earnings	$2.223B	$973.0M	$2.007B
YoY Change	10.76%	-44.3%	41.24%
Net Earnings / Revenue	3.22%	1.4%	3.01%
Basic Earnings Per Share	$1.69		$1.54
Diluted Earnings Per Share	$1.68	$740.5K	$1.53
COMMON SHARES
Basic Shares Outstanding	1.313B shares	1.309B shares	1.306B shares
Diluted Shares Outstanding	1.322B shares		1.312B shares

Balance Sheet

Concept	2021 Q1	2020 Q4	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.788B	$10.85B	$12.71B
YoY Change	-30.87%	34.73%	52.76%
Cash & Equivalents	$5.598B	$7.854B	$10.08B
Short-Term Investments	$3.190B	$3.000B	$2.632B
Other Short-Term Assets	$5.458B	$5.277B	$6.232B
YoY Change	-12.42%	3.21%	37.48%
Inventory	$17.62B	$18.50B	$16.98B
Prepaid Expenses
Receivables	$23.86B	$21.74B	$23.04B
Other Receivables	$2.450B	$2.198B	$2.838B
Total Short-Term Assets	$55.72B	$56.37B	$58.96B
YoY Change	-5.49%	12.06%	30.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.61B	$12.61B	$12.15B
YoY Change	3.83%	4.67%	6.92%
Goodwill	$79.55B	$79.55B	$79.99B
YoY Change	-0.55%	-0.25%	1.16%
Intangibles	$30.64B	$31.14B	$32.73B
YoY Change	-6.38%	-5.98%	-9.86%
Long-Term Investments	$21.03B	$20.81B	$16.84B
YoY Change	24.85%	20.2%	2.62%
Other Assets	$4.826B	$4.624B	$4.748B
YoY Change	1.64%	0.52%	4.93%
Total Long-Term Assets	$173.9B	$174.3B	$171.7B
YoY Change	1.28%	1.28%	0.12%
TOTAL ASSETS
Total Short-Term Assets	$55.72B	$56.37B	$58.96B
Total Long-Term Assets	$173.9B	$174.3B	$171.7B
Total Assets	$229.6B	$230.7B	$230.6B
YoY Change	-0.45%	3.72%	6.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$35.36B	$34.87B	$33.26B
YoY Change	6.32%	12.58%	24.01%
Accrued Expenses	$14.31B	$14.24B	$13.57B
YoY Change	5.44%	17.39%	27.35%
Deferred Revenue	$80.00M	$71.00M	$85.00M
YoY Change	-5.88%	-2.74%	13.33%
Short-Term Debt	$252.0M	$0.00	$255.0M
YoY Change	-1.18%		-91.51%
Long-Term Debt Due	$2.422B	$5.440B	$5.828B
YoY Change	-58.44%	43.88%	359.98%
Total Short-Term Liabilities	$60.10B	$62.02B	$59.56B
YoY Change	0.91%	16.35%	30.15%
LONG-TERM LIABILITIES
Long-Term Debt	$59.27B	$59.21B	$65.74B
YoY Change	-9.83%	-8.49%	-7.87%
Other Long-Term Liabilities	$2.309B	$2.351B	$2.117B
YoY Change	9.07%	8.74%	-6.41%
Total Long-Term Liabilities	$2.309B	$2.351B	$67.85B
YoY Change	-96.6%	-96.48%	-7.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$60.10B	$62.02B	$59.56B
Total Long-Term Liabilities	$2.309B	$2.351B	$67.85B
Total Liabilities	$158.4B	$161.0B	$165.2B
YoY Change	-4.07%	1.73%	4.57%
SHAREHOLDERS EQUITY
Retained Earnings	$51.20B	$49.64B	$46.46B
YoY Change	10.22%	10.05%	13.06%
Common Stock	$17.00M	$17.00M	$17.00M
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$28.10B	$28.18B	$28.18B
YoY Change	-0.28%	-0.2%	-0.14%
Treasury Stock Shares	422.0M shares	423.0M shares	424.0M shares
Shareholders Equity	$70.85B	$69.39B	$65.14B
YoY Change
Total Liabilities & Shareholders Equity	$229.6B	$230.7B	$230.6B
YoY Change	-0.45%	3.72%	4.95%

Cashflow Statement

Concept	2021 Q1	2020 Q4	2020 Q1
OPERATING ACTIVITIES
Net Income	$2.223B	$973.0M	$2.007B
YoY Change	10.76%	-44.3%	41.24%
Depreciation, Depletion And Amortization	$1.126B		$1.086B
YoY Change	3.68%		-2.25%
Cash From Operating Activities	$2.892B	$3.567B	$3.305B
YoY Change	-12.5%	35.42%	69.66%
INVESTING ACTIVITIES
Capital Expenditures	$829.0M	-$713.0M	$742.0M
YoY Change	11.73%	25.75%	3.63%
Acquisitions	$84.00M		$613.0M
YoY Change	-86.3%		394.35%
Other Investing Activities	$0.00	-$521.0M	-$5.000M
YoY Change	-100.0%	266.9%	-50.0%
Cash From Investing Activities	-$1.867B	-$1.234B	-$1.597B
YoY Change	16.91%	74.05%	79.24%
FINANCING ACTIVITIES
Cash Dividend Paid	$656.0M		$652.0M
YoY Change	0.61%		0.46%
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net	$3.049B		$1.008B
YoY Change	202.48%		14.29%
Cash From Financing Activities	-$3.185B	-3.735B	$2.675B
YoY Change	-219.07%	159.38%	227.82%
NET CHANGE
Cash From Operating Activities	$2.892B	3.567B	$3.305B
Cash From Investing Activities	-$1.867B	-1.234B	-$1.597B
Cash From Financing Activities	-$3.185B	-3.735B	$2.675B
Net Change In Cash	-$2.160B	-1.402B	$4.383B
YoY Change	-149.28%	-389.07%	134.01%
FREE CASH FLOW
Cash From Operating Activities	$2.892B	$3.567B	$3.305B
Capital Expenditures	$829.0M	-$713.0M	$742.0M
Free Cash Flow	$2.063B	$4.280B	$2.563B
YoY Change	-19.51%	33.71%	108.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000064803
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2020Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-01011
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	CVS HEALTH CORPORATION
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	05-0494040
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	One CVS Drive,
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Woonsocket,
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	RI
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02895
CY2021Q1	dei	City Area Code CityAreaCode	(401)
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	765-1500
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	CVS
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1316567871	shares
CY2021Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	18960000000	USD
CY2020Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	17640000000	USD
CY2021Q1	us-gaap	Net Investment Income NetInvestmentIncome	297000000	USD
CY2020Q1	us-gaap	Net Investment Income NetInvestmentIncome	162000000	USD
CY2021Q1	us-gaap	Revenues Revenues	69097000000	USD
CY2020Q1	us-gaap	Revenues Revenues	66755000000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	40894000000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	40347000000	USD
CY2021Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	15704000000	USD
CY2020Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	14387000000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	8922000000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	8563000000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	65520000000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	63297000000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3577000000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3458000000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	657000000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	733000000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	50000000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	54000000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2970000000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	2779000000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	746000000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	767000000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	2224000000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	2012000000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1000000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5000000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	2223000000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	2007000000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-4000000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.69
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.54
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.68
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.53
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1313000000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1306000000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1322000000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1312000000	shares
CY2021Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2020Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2021Q1	us-gaap	Profit Loss ProfitLoss	2224000000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	2012000000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-386000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-311000000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-12000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-9000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-332000000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-392000000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1832000000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1680000000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1000000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5000000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1831000000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1675000000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5598000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7854000000	USD
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	3190000000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	3000000000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23855000000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21742000000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	17618000000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	18496000000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	5458000000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5277000000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	55719000000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	56369000000	USD
CY2021Q1	us-gaap	Long Term Investments LongTermInvestments	21025000000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	20812000000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12611000000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12606000000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20542000000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20729000000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	79552000000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	79552000000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	30639000000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31142000000	USD
CY2021Q1	us-gaap	Separate Account Assets SeparateAccountAssets	4692000000	USD
CY2020Q4	us-gaap	Separate Account Assets SeparateAccountAssets	4881000000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4826000000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4624000000	USD
CY2021Q1	us-gaap	Assets Assets	229606000000	USD
CY2020Q4	us-gaap	Assets Assets	230715000000	USD
CY2021Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10804000000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	11138000000	USD
CY2021Q1	cvs	Pharmacy Claimsand Discounts Payable Current PharmacyClaimsandDiscountsPayableCurrent	16282000000	USD
CY2020Q4	cvs	Pharmacy Claimsand Discounts Payable Current PharmacyClaimsandDiscountsPayableCurrent	15795000000	USD
CY2021Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	8272000000	USD
CY2020Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	7936000000	USD
CY2021Q1	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	4440000000	USD
CY2020Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	4270000000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14312000000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14243000000	USD
CY2021Q1	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1534000000	USD
CY2020Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1557000000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1786000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1638000000	USD
CY2021Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	252000000	USD
CY2020Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2021Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2422000000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5440000000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	60104000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62017000000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18587000000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18757000000	USD
CY2021Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	59270000000	USD
CY2020Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	59207000000	USD
CY2021Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6610000000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6794000000	USD
CY2021Q1	us-gaap	Separate Accounts Liability SeparateAccountsLiability	4692000000	USD
CY2020Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	4881000000	USD
CY2021Q1	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	6870000000	USD
CY2020Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	7007000000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2309000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2351000000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	158442000000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	161014000000	USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1735000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1313000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1733000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1310000000	shares
CY2021Q1	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	46727000000	USD
CY2020Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	46513000000	USD
CY2021Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	422000000	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	423000000	shares
CY2021Q1	us-gaap	Treasury Stock Value TreasuryStockValue	28102000000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	28178000000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	51203000000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	49640000000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1022000000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1414000000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	70850000000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	69389000000	USD
CY2021Q1	us-gaap	Minority Interest MinorityInterest	314000000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	312000000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71164000000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	69701000000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	229606000000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230715000000	USD
CY2021Q1	us-gaap	Proceeds From Customers ProceedsFromCustomers	66487000000	USD
CY2020Q1	us-gaap	Proceeds From Customers ProceedsFromCustomers	63751000000	USD
CY2021Q1	cvs	Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies	39171000000	USD
CY2020Q1	cvs	Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies	36969000000	USD
CY2021Q1	cvs	Paymentsfor Insurance Benefits PaymentsforInsuranceBenefits	15456000000	USD
CY2020Q1	cvs	Paymentsfor Insurance Benefits PaymentsforInsuranceBenefits	14303000000	USD
CY2021Q1	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	8270000000	USD
CY2020Q1	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	8187000000	USD
CY2021Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	222000000	USD
CY2020Q1	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	206000000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	876000000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	1128000000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	44000000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	65000000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2892000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3305000000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2177000000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1288000000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3131000000	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1535000000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	829000000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	742000000	USD
CY2021Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	84000000	USD
CY2020Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	613000000	USD
CY2021Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
CY2020Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-5000000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1867000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1597000000	USD
CY2021Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	252000000	USD
CY2020Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	255000000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3946000000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3049000000	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1008000000	USD
CY2021Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	656000000	USD
CY2020Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	652000000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	212000000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	154000000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3000000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16000000	USD
CY2021Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2020Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-4000000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3244000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2675000000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2219000000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4383000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8130000000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5954000000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5911000000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10337000000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	2224000000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	2012000000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1126000000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1086000000	USD
CY2021Q1	cvs	Numberof Patients Servedper Year NumberofPatientsServedperYear	1000000	patient
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	87000000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	96000000	USD
CY2021Q1	cvs	Deferredincometaxesandothernoncashitems Deferredincometaxesandothernoncashitems	-166000000	USD
CY2020Q1	cvs	Deferredincometaxesandothernoncashitems Deferredincometaxesandothernoncashitems	-35000000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2093000000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2715000000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-879000000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-541000000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	223000000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1119000000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	576000000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1928000000	USD
CY2021Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	294000000	USD
CY2020Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	139000000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	188000000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1372000000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2892000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3305000000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	69701000000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	2224000000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-392000000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	214000000	USD
CY2021Q1	cvs	Espp Issuance Net Of Treasury Stock Value Acquired Cost Method ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod	76000000	USD
CY2021Q1	us-gaap	Dividends Common Stock DividendsCommonStock	660000000	USD
CY2021Q1	cvs	Noncontrollinginterest Other Period Increase Decrease NoncontrollinginterestOtherPeriodIncreaseDecrease	1000000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71164000000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64170000000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	2012000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-332000000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	208000000	USD
CY2020Q1	cvs	Espp Issuance Net Of Treasury Stock Value Acquired Cost Method ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod	53000000	USD
CY2020Q1	us-gaap	Dividends Common Stock DividendsCommonStock	657000000	USD
CY2021Q1	cvs	Numberof Pharmacy Plan Members NumberofPharmacyPlanMembers	108000000	people
CY2020Q1	cvs	Noncontrollinginterest Other Period Increase Decrease NoncontrollinginterestOtherPeriodIncreaseDecrease	23000000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	65474000000	USD
CY2021Q1	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2019Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020Q1	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2020Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2019Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2021Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2020Q1	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	17000000	USD
CY2021Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	Segment
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5598000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7854000000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	313000000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	276000000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5911000000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8130000000	USD
CY2021Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7748000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7101000000	USD
CY2021Q1	cvs	Vendorand Manufacturer Receivables VendorandManufacturerReceivables	10556000000	USD
CY2020Q4	cvs	Vendorand Manufacturer Receivables VendorandManufacturerReceivables	9815000000	USD
CY2021Q1	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	3101000000	USD
CY2020Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	2628000000	USD
CY2021Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2450000000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2198000000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23855000000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21742000000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	375000000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	358000000	USD
CY2021Q1	us-gaap	Net Investment Income NetInvestmentIncome	297000000	USD
CY2021Q1	us-gaap	Revenues Revenues	69097000000	USD
CY2020Q1	us-gaap	Net Investment Income NetInvestmentIncome	162000000	USD
CY2020Q1	us-gaap	Revenues Revenues	66755000000	USD
CY2021Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7748000000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	7101000000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	80000000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	73000000	USD
CY2021Q1	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	93000000	USD
CY2020Q1	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	99000000	USD
CY2021Q1	cvs	Contractwith Customer Liability Redemptionand Breakage ContractwithCustomerLiabilityRedemptionandBreakage	84000000	USD
CY2020Q1	cvs	Contractwith Customer Liability Redemptionand Breakage ContractwithCustomerLiabilityRedemptionandBreakage	87000000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	80000000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	85000000	USD
CY2021Q1	cvs	Health Insurer Fee HealthInsurerFee	0	USD
CY2020Q1	cvs	Health Insurer Fee HealthInsurerFee	271000000	USD
CY2021Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	9000000	USD
CY2020Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	20000000	USD
CY2021Q1	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	18000000	USD
CY2020Q1	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	21000000	USD
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	3190000000	USD
CY2021Q1	us-gaap	Long Term Investments LongTermInvestments	21025000000	USD
CY2021Q1	us-gaap	Investments Investments	24215000000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	3000000000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	20812000000	USD
CY2020Q4	us-gaap	Investments Investments	23812000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Amortized Cost Net DebtSecuritiesAvailableForSaleAmortizedCostNet	20349000000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1230000000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	75000000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21504000000	USD
CY2020Q4	cvs	Debt Securities Available For Sale Amortized Cost Net DebtSecuritiesAvailableForSaleAmortizedCostNet	19396000000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1803000000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21188000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q1	cvs	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date Within One Year Amortized Cost Net DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet	1199000000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1213000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Five Years Amortized Cost Net DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNet	6997000000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	7289000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Maturity Allocated And Single Maturity Dateafter Five Through Ten Years Amortized Cost Net DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateafterFiveThroughTenYearsAmortizedCostNet	4150000000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	4367000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Allocated And Single Maturity Date Maturity After10 Years Amortized Cost Net DebtSecuritiesAvailableForSaleAllocatedAndSingleMaturityDateMaturityAfter10YearsAmortizedCostNet	4021000000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	4565000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Amortized Cost Net DebtSecuritiesAvailableForSaleAmortizedCostNet	20349000000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21504000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	2396	security
CY2021Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	4537000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	74000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	48	security
CY2021Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	51000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	2444	security
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	4588000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	75000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	468	security
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	869000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	10000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	59	security
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	46000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	527	security
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	915000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	11000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear	9000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss	0	USD
CY2021Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears	1571000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss	13000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears	1316000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss	25000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears	478000000	USD
CY2021Q1	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss	16000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	4588000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	75000000	USD
CY2021Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	258000000	USD
CY2020Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	206000000	USD
CY2021Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	8000000	USD
CY2020Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	8000000	USD
CY2021Q1	cvs	Investment Income Excluding Capital Gainsor Losses InvestmentIncomeExcludingCapitalGainsorLosses	250000000	USD
CY2020Q1	cvs	Investment Income Excluding Capital Gainsor Losses InvestmentIncomeExcludingCapitalGainsorLosses	198000000	USD
CY2021Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	47000000	USD
CY2020Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-36000000	USD
CY2021Q1	us-gaap	Investment Income Net InvestmentIncomeNet	297000000	USD
CY2020Q1	us-gaap	Investment Income Net InvestmentIncomeNet	162000000	USD
CY2021Q1	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-30000000	USD
CY2021Q1	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2020Q1	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-45000000	USD
CY2020Q1	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-41000000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1348000000	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	723000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	22000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	20000000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	9000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	35000000	USD
CY2021Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the three months ended March 31, 2021 and 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,639 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,300 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,305 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,015 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,267 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,581 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,272 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the three months ended March 31, 2021 and 2020 in the table above exclude (i) $7 million and $10 million, respectively, related to a premium deficiency reserve related to the Company’s Medicaid products, (ii) $13 million and $9 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets and (iii) $45 million and $68 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets.</span></div>
CY2021Q1	us-gaap	Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet	6500000000	USD
CY2020Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2021Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2020Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2021Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.50
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-392000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-332000000	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10000000	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12000000	shares
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2223000000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2007000000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1313000000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1306000000	shares
CY2021Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9000000	shares
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	6000000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1322000000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1312000000	shares
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.69
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.54
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.68
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.53
CY2021Q1	cvs	Guarantor Obligations Numberof Leases GuarantorObligationsNumberofLeases	74	store
CY2012	cvs	Loss Contingency Audit Methodology Sample Size LossContingencyAuditMethodologySampleSize	200	member
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	Segment
CY2021Q1	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	68800000000	USD
CY2021Q1	us-gaap	Net Investment Income NetInvestmentIncome	297000000	USD
CY2021Q1	us-gaap	Revenues Revenues	69097000000	USD
CY2021Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4205000000	USD
CY2020Q1	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	66593000000	USD
CY2020Q1	us-gaap	Net Investment Income NetInvestmentIncome	162000000	USD
CY2020Q1	us-gaap	Revenues Revenues	66755000000	USD
CY2020Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4113000000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3577000000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3458000000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	587000000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	586000000	USD
CY2021Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	41000000	USD
CY2020Q1	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	69000000	USD
CY2021Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4205000000	USD
CY2020Q1	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	4113000000	USD

Files In Submission

Name	View Source	Status
0000064803-21-000017-index-headers.html	Edgar Link	pending
0000064803-21-000017-index.html	Edgar Link	pending
0000064803-21-000017.txt	Edgar Link	pending
0000064803-21-000017-xbrl.zip	Edgar Link	pending
a03312021ex101.htm	Edgar Link	pending
a03312021ex102.htm	Edgar Link	pending
a03312021ex151.htm	Edgar Link	pending
a03312021ex311.htm	Edgar Link	pending
a03312021ex312.htm	Edgar Link	pending
a03312021ex321.htm	Edgar Link	pending
a03312021ex322.htm	Edgar Link	pending
cvs-20210331.htm	Edgar Link	pending
cvs-20210331.xsd	Edgar Link	pending
cvs-20210331_cal.xml	Edgar Link	unprocessable
cvs-20210331_def.xml	Edgar Link	unprocessable
cvs-20210331_g1.jpg	Edgar Link	pending
cvs-20210331_htm.xml	Edgar Link	completed
cvs-20210331_lab.xml	Edgar Link	unprocessable
cvs-20210331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVS
CVS HEALTH Corp Stock $cvs

2021 Q1 Form 10-Q Financial Statement

#000006480321000017 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS CVS HEALTH Corp Stock $cvs

2021 Q1 Form 10-Q Financial Statement

#000006480321000017 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS
CVS HEALTH Corp Stock $cvs